Here, we report the development of a unique formulation for our first-in-class FSH-blocking humanized antibody, MS-Hu6, which we propose to move to the clinic for osteoporosis, obesity, and Alzheimer’s disease. This evidence concerns the gene BRD2 and early-onset autosomal dominant Alzheimer disease.